Phase 3 study on previously untreated chronic lymphocytic leukemia showed sustained PFS with venetoclax-obinutuzumab.

The superior effects of obinutuzumab seen in the laboratory have been confirmed in clinical trials and, in 2013, the drug was the first drug to be awarded Breakthrough Therapy Designation by the ...

The head-to-head GALLIUM trial showed the newer drug Gazyva (obinutuzumab)produced a 34% reduction in the risk of disease progression or death in patients with previously untreated FL compared to ...

Idiopathic Membranous Nephropathy Treatment Market is projected to witness substantial growth over the next few years, driven ...

In the multicenter, open-label, single-arm MOLTO study (ClinicalTrials.gov Identifier: NCT04082897), researchers treated 28 patients with previously-untreated DLBCL-RT with atezolizumab plus ...

Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...

Results from the LTE (long-term extension rollover) study of patients with treatment-naïve and R/R CLL also showed that treatment with BRUKINSA as a single agent or as an investigational treatment in ...

Although the full results won't be presented at the upcoming ACR conference, a post hoc analysis of the obinutuzumab phase 2 data will be shared. Attendees can also look forward to the unveiling ...